The US$3.5 billion Lehigh Valley plant fits that story: it underlines Lilly's intent to sustain injectable weightloss volumes well into the next decade, but it barely moves the needle on near term catalysts like upcoming orforglipron decisions and quarterly tirzepatide trends
Both medications stop working the moment patients stop using them
Key takeaways Ozempic (semaglutide) is an injectable medication approved by the FDA to treat diabetes but is also prescribed off-label for weight loss management
Before starting either agent, providers should evaluate fasting glucose, A1c, insulin resistance markers (HOMA-IR), lipid profile, and cardiovascular history
However, vertigo is not among the most commonly reported side effects of semaglutide
20462054, DOI:10.1002/oby.24360, PMID 40685589